European Journal of Pharmaceutics and Biopharmaceutics最新文献

{"title":"Repeated sequential administration of pegylated emulsion of SU5416 and liposomal paclitaxel enhances anti-tumor effect in 4T1 breast cancer-bearing mice","authors":"Masato Maruyama ,&nbsp;Reiya Torii ,&nbsp;Hazuki Matsui ,&nbsp;Hiroki Hayashi ,&nbsp;Ken-ichi Ogawara ,&nbsp;Kazutaka Higaki","doi":"10.1016/j.ejpb.2025.114663","DOIUrl":"10.1016/j.ejpb.2025.114663","url":null,"abstract":"<div><div>To improve vascular normalization strategy for intractable triple-negative breast cancer 4T1, we examined the anti-tumor effects of repeated sequential administration of polyethylene glycol (PEG)-modified emulsion of SU5416 (PE-SU5416), a vascular endothelial growth factor (VEGF) receptor-2 kinase inhibitor, and PEG-modified liposomal paclitaxel (PL-PTX) in mice bearing 4T1 cells. Three sequential administrations (Seq×3) of PE-SU5416 and PL-PTX exhibited significantly higher anti-tumor activity than a single sequential administration (Seq×1). The tumor vasculatures were structurally normalized until after two PE-SU5416 (PE-SU5416×2) or sequential (Seq×2) administrations, while the improvement in vascular function, such as oxygen supply, blood flow, and PEG-liposomal distribution, was evident until after three administrations of PE-SU5416 (PE-SU5416×3) and Seq×3. Although some discrepancies between the structural and functional improvement in tumor vasculatures were observed after PE-SU5416×3 and Seq×3, cancer-associated fibroblasts (CAFs) and collagen levels were significantly reduced after PE-SU5416×2, PE-SU5416×3, Seq×2, and Seq×3, suggesting that a possible decrease in interstitial fluid pressure due to the reduction in CAFs and collagen would have compensated for vascular function. Furthermore, PE-SU5416×2, PE-SU5416×3, Seq×2, and Seq×3 significantly decreased tumor growth factor-β (TGF-β), an activator of CAFs, in tumor tissues, suggesting that the reduction in TGF-β levels by PE-SU5416 suppresses CAF activation.</div></div>","PeriodicalId":12024,"journal":{"name":"European Journal of Pharmaceutics and Biopharmaceutics","volume":"209 ","pages":"Article 114663"},"PeriodicalIF":4.4,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143374068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The revival of the mini-tablets: Recent advancements, classifications and expectations for the future","authors":"Valentinë Lura ,&nbsp;Ard Lura ,&nbsp;Jörg Breitkreutz ,&nbsp;Viviane Klingmann","doi":"10.1016/j.ejpb.2025.114655","DOIUrl":"10.1016/j.ejpb.2025.114655","url":null,"abstract":"&lt;div&gt;&lt;div&gt;Mini-tablets have recently raised huge interest in pharmaceutical industry. The present review aims to identify the rational, the opportunities and challenges of this emerging small solid drug dosage form by a structured literature review following the PRISMA algorithm. In total, more than 5,000 literature and patent sources have been found starting with the very first in the 60s of the past century, followed by the first multiparticular products using mini-tablets with pancreatin (Panzytrat® by the former BASF subsidiary Knoll/Nordmark) authorized in 1985. There seems to be a second boost of common interest in the 2000s when clinical studies demonstrated that one or more mini-tablets could enable superior drug administration even in very young patients including neonates over the former gold standard, a liquid drug preparation. Several pharmaceutical companies immediately started clinical development programs using the mini-tablet concept and the first products have been recently authorized by the competent authorities. Superiority was given as the mini-tablets ease the swallowing procedure compared to conventional tablets, enable various modified drug release opportunities including taste-masking by film-coating technology and provide excellent drug stability compared to liquid oral dosage forms. Due to these product attributes they are particularly beneficial to children and their caregivers. Furthermore, there is potential for precise individual drug dosing by counting adequate amounts of the multiple drug carriers. Most recently, two novel products with different concepts were authorized by the EMA and entered the market which are highlighted in this review: the first orodispersible mini-tablet with enalapril maleate for congenital heart failure (Aqumeldi® from Proveca Pharma) and the first single unit mini-tablet with matrix-type controlled melatonin release for insomnia (Slenyto® from Neurim Pharmaceuticals).&lt;/div&gt;&lt;div&gt;Our review reveals, that the majority of the published scientific papers use co-processed, ready-to-use excipients for the orodispersible mini-tablet formulations. However, traditional fillers such as microcrystalline cellulose or lactose have also been used for immediate release mini-tablets after adding a (super)disintegrant and a lubricant. The manufacturing of mini-tablets is conducted on conventional rotary tablet presses, predominantly equipped with multi-tip toolings to improve the yield or production speed. Scaling-up has been successfully realized from compaction simulators to pilot and production scale. Film-coatings enabling gastric resistance, taste masking or sustained-release properties have been realized in both fluid-bed and drum coaters using the same polymers as for conventional tablets. There is still a significant lack in regulatory guidance despite the recent success of the mini-tablet concept, starting from suitable characterization methods in the pharmacopoeias up to the design and conduct of","PeriodicalId":12024,"journal":{"name":"European Journal of Pharmaceutics and Biopharmaceutics","volume":"210 ","pages":"Article 114655"},"PeriodicalIF":4.4,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143374071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Towards a digital twin of primary drying in lyophilization using coupled 3-D equipment CFD and 1-D vial-scale simulations","authors":"Matej Zadravec ,&nbsp;Efimia Metsi-Guckel ,&nbsp;Blaz Kamenik ,&nbsp;Johan Remelgas ,&nbsp;Johannes Khinast ,&nbsp;Nick Roscioli ,&nbsp;Matthew Flamm ,&nbsp;Harshil Renawala ,&nbsp;Jeff Najarian ,&nbsp;Atul Karande ,&nbsp;Avik Sarkar","doi":"10.1016/j.ejpb.2025.114662","DOIUrl":"10.1016/j.ejpb.2025.114662","url":null,"abstract":"<div><div>A digital twin of lyophilization units was developed to facilitate the scale-up of the lyophilization process from the laboratory to the commercial scale. Our focus was on ensuring successful technology transfer for manufacture of high-quality drug products. Traditionally, lyophilization models have been specific either to the equipment or to the vial. In this study, we integrated the equipment and the vial models in a way that they mutually influenced each other via boundary conditions (two-way coupling). We conducted two sets of calculations. Firstly, we performed steady-state simulations using Computational Fluid Dynamics (CFD) to simulate an ice slab test, which helped determine the equipment capability curve. Secondly, we carried out transient, coupled simulations using a coupled 3-D CFD and 1-D vial scale simulation model to mimic the primary drying phase in a lyophilizer. Using the coupled 3-D CFD and 1-D vial scale model, we were able to determine the product temperature, the sublimation rate and the cycle time based on the temporal and spatial conditions in the lyophilizer. The coupled approach was then applied to capture the effects of process disturbances and failure conditions in the lyophilizer, which enables a more robust process design.</div></div>","PeriodicalId":12024,"journal":{"name":"European Journal of Pharmaceutics and Biopharmaceutics","volume":"208 ","pages":"Article 114662"},"PeriodicalIF":4.4,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143374073","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rational design of PLA-based ASDs for pharmaceutical 3D printing: Insights from phase diagram modeling","authors":"Alma Lucia Villela Zumaya ,&nbsp;Anton Iemtsev ,&nbsp;Michal Fulem ,&nbsp;Fatima Hassouna","doi":"10.1016/j.ejpb.2025.114657","DOIUrl":"10.1016/j.ejpb.2025.114657","url":null,"abstract":"<div><div>The integration of 3D printing into the pharmaceutical sciences opens new possibilities for personalized medicine. Poly(lactide) (PLA), a biodegradable and biocompatible polymer, is highly suitable for biomedical applications, particularly in the context of 3D printing. However, its processability often requires the addition of plasticizers. This study investigates the use of phase diagram modeling as a tool to guide the rational selection of plasticizers and to assess their impact on the thermodynamic and kinetic stability of PLA-based amorphous solid dispersions (ASDs) containing active pharmaceutical ingredients (APIs). Thermodynamic stability against API recrystallization was predicted based on the API solubility in PLA and Plasticizer-PLA carriers using the Conductor-like Screening Model for Real Solvents (COSMO-RS), while the kinetic stability of the ASDs was evaluated by modeling the glass transition temperatures of the mixtures. Two APIs, indomethacin (IND) and naproxen (NAP), with differing glass-forming abilities (i.e., recrystallization tendencies), and three plasticizers, triacetin (TA), triethyl citrate (TEC), and poly(L-lactide-co-caprolactone) (PLCL), were selected for investigation. The physical stability of ASD formulations containing 9 wt% API and plasticizer to PLA in two ratios, 10:81 and 20:71 w/w %, was monitored over time using differential scanning calorimetry and X-ray powder diffraction and compared with phase diagram predictions. All formulations were predicted to be thermodynamically unstable; however, those containing no plasticizer or with TEC and TA at 10 wt% were predicted to exhibit some degree of kinetic stability. Long-term physical studies corroborated these predictions. The correlation between the predicted phase behavior and long-term physical stability highlights the potential of phase diagram modeling as a tool for the rational design of ASDs in pharmaceutical 3D printing.</div></div>","PeriodicalId":12024,"journal":{"name":"European Journal of Pharmaceutics and Biopharmaceutics","volume":"208 ","pages":"Article 114657"},"PeriodicalIF":4.4,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143350785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficient nose-to-brain delivery of nine residues peptide (JAL-TA9) exhibiting hydrolytic activity against amyloid-β","authors":"Yusuke Hatakawa ,&nbsp;Akiko Tanaka ,&nbsp;Tomoyuki Furubayashi ,&nbsp;Hidemasa Katsumi ,&nbsp;Rina Nakamura ,&nbsp;Motomi Konishi ,&nbsp;Toshifumi Akizawa ,&nbsp;Toshiyasu Sakane","doi":"10.1016/j.ejpb.2025.114661","DOIUrl":"10.1016/j.ejpb.2025.114661","url":null,"abstract":"<div><div>JAL-TA9 (YKGSGFRMI), is a 9-residue catalytic peptide that cleaves amyloid β (Aβ) 42. Nasal administration was chosen to bypass the blood–brain barrier for efficient brain delivery of JAL-TA9 to treat Alzheimer’s disease (AD). Plasma clearance of JAL-TA9 after intravenous bolus injection in rats was very rapid, with a half-life of &lt;1 min. The stability of JAL-TA9 in cerebrospinal fluid (CSF) was much better than that in plasma and whole blood <em>in vitro</em>, suggesting the advantage of direct nasal delivery to avoid rapid elimination from the blood. JAL-TA9 in CSF was 0.115 μg/mL 10 min after nasal administration to rats, but below the detection limit after intravenous injection, indicating a significant direct delivery of JAL-TA9 to the brain. In mice brain, JAL-TA9 concentration was higher after nasal administration than that after intraperitoneal administration. Additionally, peak concentration in the olfactory bulb (OB) after nasal application was at 5 min, whereas in the frontal and occipital brains peaked at 30 and 60 min, respectively, suggesting sequential backward translocation of JAL-TA9 within the brain after direct transport from the nasal cavity to the OB. Therefore, nasal administration allows the efficient delivery of JAL-TA9 to the brain and may be a potential in AD treatment.</div></div>","PeriodicalId":12024,"journal":{"name":"European Journal of Pharmaceutics and Biopharmaceutics","volume":"208 ","pages":"Article 114661"},"PeriodicalIF":4.4,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143364096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A comprehensive review of caffeine population pharmacokinetics in preterm infants: Factors affecting clearance","authors":"Yaodong He ,&nbsp;Xianhuan Shen ,&nbsp;Jiahao Zhu ,&nbsp;Lian Zhang ,&nbsp;Xixuan Wang ,&nbsp;Tao Zhou ,&nbsp;Jianping Zhang ,&nbsp;Wenzhou Li ,&nbsp;Xiaomei Fan","doi":"10.1016/j.ejpb.2025.114659","DOIUrl":"10.1016/j.ejpb.2025.114659","url":null,"abstract":"<div><div>Caffeine is an FDA-approved drug for preventing and treating apnea in preterm infants. However, the pharmacokinetic (PK) characteristics of caffeine in preterm infants differ significantly from those in adults. Several population pharmacokinetic (PopPK) models have been developed to investigate potential covariates influencing PK parameters. This review aimed to summarize PopPK studies of caffeine in preterm infants and explore the identified influencing covariates. It has been observed that most caffeine pharmacokinetics followed a one-compartment model (1-CMT), although one study utilized a three-compartment model (3-CMT). Various covariates including birth weight, current weight, genetic polymorphism, combination medications, feeding patterns, and pathological conditions have been identified to affect caffeine PK parameters in preterm infants. Developing an individualized dosing regimen for preterm infants is essential for safe and effective treatment. Future PopPK studies of caffeine in preterm infants should focus on sampling and feeding patterns and further explore the effects of other covariates like gestational and postnatal age on caffeine PK parameters, which should be taken into account in the individualized dosing regimen of caffeine.</div></div>","PeriodicalId":12024,"journal":{"name":"European Journal of Pharmaceutics and Biopharmaceutics","volume":"208 ","pages":"Article 114659"},"PeriodicalIF":4.4,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143364091","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"β-Cyclodextrin nanosponges for the ocular delivery of therapeutic Micro-RNA in a Mouse model of retinitis Pigmentosa: A proof of concept study","authors":"Ilaria Piano ,&nbsp;Beatrice Polini ,&nbsp;Francesca Corsi ,&nbsp;Sara Carpi ,&nbsp;Giovanni Petrarolo ,&nbsp;Luca Quattrini ,&nbsp;Ilaria D’Agostino ,&nbsp;Maria Cristina Gamberini ,&nbsp;Cecilia Baraldi ,&nbsp;Grazia Chiellini ,&nbsp;Paola Nieri ,&nbsp;Concettina La Motta ,&nbsp;Claudia Gargini","doi":"10.1016/j.ejpb.2025.114660","DOIUrl":"10.1016/j.ejpb.2025.114660","url":null,"abstract":"<div><div>The exploitation of micro-RNA (miR) sequences as therapeutics has become highly attractive for the treatment of several diseases, including those still lacking effective cures such as retinitis pigmentosa (RP). Interestingly, miR-155-5p plays a role in photo-oxidative inflammation in wild-type mice and is up-regulated in rd10 mice showing peak rod degeneration, suggesting its inhibition by the corresponding anti-miR as a viable therapeutic strategy for RP. However, biomedical application of (anti-)miRs is limited by their oligonucleotide nature, suffering from low solubility and bioavailability along with a very low half-life <em>in vivo</em> due to enzymatic degradation. Thereby, the need for suitable delivery systems led to the development of various nanocarriers, including oligosaccharide-based polymers. In this context, we designed and prepared an innovative nanosponge (NS) with a β-cyclodextrin (β-CD) motif payload with a <em>bridge-like</em> molecule, the amphipathic adamantane derivative (ADM), able to establish strong interactions with both NS and the therapeutic miR, thereby delivering and eventually releasing it close to the active site. Through an <em>in vivo</em> study, we both validated the NS system as a useful tool for miR topical administration by eye drop formulation and the functional activity of anti-miR-155-5p in RP.</div></div>","PeriodicalId":12024,"journal":{"name":"European Journal of Pharmaceutics and Biopharmaceutics","volume":"208 ","pages":"Article 114660"},"PeriodicalIF":4.4,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143364163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Curcumin-loaded zein and shellac composite nanoparticles for ulcerative colitis treatment","authors":"Xiaoyan Mu ,&nbsp;Hemin Roghzai ,&nbsp;Lingwen Zeng ,&nbsp;Xiaoqiang Sun ,&nbsp;Xiubo Zhao","doi":"10.1016/j.ejpb.2025.114658","DOIUrl":"10.1016/j.ejpb.2025.114658","url":null,"abstract":"<div><div>This study highlights the efficacy of microfluidic technology in creating curcumin (Cur) loaded zein + shellac (Z + S) hybrid nanoparticles (NPs), presenting a promising avenue for enhancing Cur’s availability in the food industry, especially in beverages, and positioning it as a potent antioxidant strategy for applications such as the treatment of enteritis. The study revealed that an increase in the proportion of shellac led to a gradual increase in the particle size of Z + S NPs, while the polydispersity index (PDI) initially decreasing and then increasing. When Cur is encapsulated, an increase in the proportion of shellac resulted in a gradual decrease in particle size and PDI, accompanied by an increase in encapsulation efficiency (EE). When the ratio of zein and shellac remained constant, elevating the Cur concentration led to a gradual decrease in EE and a gradual increase in drug loading. The consistently low Zeta potential (below −20 mV) confirmed the colloidal stability of the NPs, making them suitable for prolonged storage. The NPs exhibited excellent biocompatibility with normal cells and demonstrated effective free radical scavenging capabilities. Mixing of shellac and zein regulated the release profile of Cur from the NPs, mapping the food fate in human body, enhancing the treatment efficacy of ulcerative colitis. In vivo experiment demonstrated that the NPs are able to effectively relieve the dextran sulphate sodium induced enteritis, providing a promising approach for the treatment of ulcerative colitis.</div></div>","PeriodicalId":12024,"journal":{"name":"European Journal of Pharmaceutics and Biopharmaceutics","volume":"209 ","pages":"Article 114658"},"PeriodicalIF":4.4,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143364093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Carrier-free nanodrug based on small molecule drug and sonosensitizer for enhanced the ferroptosis-driven multimodal synergistic therapy of prostate cancer","authors":"Yao-Lin Wu,&nbsp;Rui-Rui Zhao,&nbsp;Xiao Wu,&nbsp;Chun-Lei Liu,&nbsp;Chun-Zhao Liu","doi":"10.1016/j.ejpb.2025.114656","DOIUrl":"10.1016/j.ejpb.2025.114656","url":null,"abstract":"<div><div>Ferroptosis plays a significant role in overcoming the therapeutic resistance of cancer cells. Herein, a carrier-free nanoparticle based on small molecule drug sorafenib (SRF) and sonosensitizer rose bengal (RB) was constructed (named SR NPs) for ferroptosis-driven chemotherapy and sonodynamic synergistic therapy (SDT) of prostate cancer (PCa). SR NPs could be enriched in tumor cells and efficiently inhibit tumor cell proliferation. These nanodrugs could significantly reduce glutathione (GSH) synthesis, and inhibit glutathione peroxidase 4 (GPX4) expression by inhibiting the glutamate/cysteine antiporter system (System Xc^-) pathway of ferroptosis. Moreover, SR NPs-mediated ferroptosis significantly improved the amount of reactive oxygen species (ROS) generated by SDT, inhibited cell migration and adhesion, enhanced the accumulation of lipid peroxides (LPO) and augmented chemo-sonodynamic therapy. Notably, <em>in vivo</em> studies demonstrated that SR NPs enhanced tumor accumulation, exhibited good biocompatibility, and showed high anti-tumor efficacy in PC-3 tumor-bearing mice. This work offered a new strategy to enhance the treatment efficacy of prostate cancer (PCa) through ferroptosis-chemotherapy-sonodynamic synergistic therapy.</div></div>","PeriodicalId":12024,"journal":{"name":"European Journal of Pharmaceutics and Biopharmaceutics","volume":"208 ","pages":"Article 114656"},"PeriodicalIF":4.4,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143254911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the physicochemical interactions and loading strategies of mesoporous silicon dioxide nanoparticles for drug delivery","authors":"Svetlana Yu. Kovtareva ,&nbsp;Eldar E. Kopishev ,&nbsp;Hongbo Zhang ,&nbsp;Sergey K. Filippov","doi":"10.1016/j.ejpb.2025.114654","DOIUrl":"10.1016/j.ejpb.2025.114654","url":null,"abstract":"<div><div>Mesoporous silica nanoparticles play an important role in drug delivery due to their high surface area, porous structure, tunable pore size, chemical stability and functionalization capability. Such properties make them a good candidate for drug encapsulation. However, molecular binding is another parameter that govern drug loading apart of pores’ structure and size. There is a lack of comprehensive reviews on that topic nowadays. This paper overviews the latest publications on the physicochemical aspects of the interaction of mesoporous silica nanoparticles with drugs. The review is focused primarily on a such parameters of the intermolecular binding between a drug and silica nanoparticle as a binding constant, enthalpy and entropy changes and experimental methods with the emphasis on the principles of thermodynamic parameters characterization. Such information would be very important for the development and optimization of drug delivery strategies based on mesoporous silica nanoparticles.</div></div>","PeriodicalId":12024,"journal":{"name":"European Journal of Pharmaceutics and Biopharmaceutics","volume":"208 ","pages":"Article 114654"},"PeriodicalIF":4.4,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143254960","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}